A Phase 1 first time in human study to evaluate the safety, pharmacokinetics and immunogenicity of MEDI5083 alone and in combination with durvalumab in select advanced solid tumors

Type of Cancer
Solid Tumor

Sponsor
Medimmune

Protocol Number
D6840C00001

To Learn More Call
(201)-510-0950